Innovent Biologics, a leading biopharmaceutical company, has announced that its partner Ollin has released final 20-week data from the Phase 1b JADE study, comparing Innovent’s OLN324 to faricimab (Vabysmo) in patients with diabetic macular edema (DME) or wet age-related macular degeneration (wAMD).
The data revealed OLN324, a higher-potency, smaller-format VEGF/Ang2 bispecific antibody, delivered faster, stronger, and more durable improvements in retinal health. In particular, OLN324 showed superior control of wAMD pigment epithelial detachments (PEDs), an area notoriously difficult to treat.
Topline results from the Week 12 primary endpoint, announced earlier this year, showed OLN324 produced superior anatomical outcomes in DME, equivalent retinal drying in wAMD, rapid vision gains in both diseases, and a favorable safety profile with no cases of intraocular inflammation.
The JADE trial enrolled 164 U.S. patients who initially received three monthly doses of OLN324 or faricimab, followed by 12 weeks off treatment with retreatment allowed only if disease recurred.
In DME, OLN324 maintained greater retinal drying and sustained vision gains compared to faricimab. Remarkably, 93% of OLN324 patients required no retreatment versus 89% for faricimab.
In wAMD, OLN324 continued to deliver comparable retinal drying and numerically greater vision gains through Week 20, with a mean +2.2 letter advantage over faricimab for the 4 mg dose. Retreatment-free follow-up was similar between groups (82% vs. 81%).
OLN324 maintained a strong safety profile, with zero intraocular inflammation cases, compared to one case in a faricimab patient.
“These new JADE study data further strengthen the differentiated profile of OLN324, highlighting its robust anatomic efficacy and durability across both DME and wAMD. Combined with a favorable safety profile, these results underscore OLN324's potential to become a first-line treatment option for these vision-threatening diseases,” said Jason Ehrlich, Co-founder and CEO of Ollin Biosciences.
“We look forward to advancing OLN324 into global Phase 3 studies in both DME and wAMD later this year… we are actively planning, in partnership with Innovent Biologics, to include China and South Korea.”
Lei Qian, Chief R&D Officer at Innovent Biologics, added, “We are pleased to see that the latest 20-week data for OLN324 (IBI324) further highlight its differentiated profile and clinical potential. We look forward to continuing our close collaboration with Ollin… to accelerate the global Phase 3 clinical development of this best-in-disease therapy for retinal diseases.”
New analyses showed OLN324 reduced PED thickness by roughly 50% faster than faricimab at Week 12, with more durable improvements through Week 20.
“As a field, we've been looking for meaningful advancements that further improve anatomic outcomes in wAMD,” said David Eichenbaum, Director of Research, Retina Vitreous Associates of Florida.
“These data suggest that OLN324's more potent Ang2 inhibition and smaller molecular format may translate into breaking through the efficacy ceiling experienced with current treatments and offering a clinically-relevant benefit in PED improvement – the most difficult to treat component of wAMD.”
